# Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304

> **NCT01457989** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1 (actual)

## Conditions studied

- Epilepsy, Partial

## Interventions

- **DRUG:** retigabine/ezogabine

## Key facts

- **NCT ID:** NCT01457989
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2012-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01457989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01457989, "Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01457989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*